Radiopharmaceuticals in Nuclear Medicine Market to Surpass US$ 11,504.8 Million by 2027

-

There are numerous radiopharmaceuticals available for both therapeutic and diagnostic purposes, each with distinct and overlapping indications for specific disorders like Alzheimer's (Vizamyl, Amyvid, and Neuraceq). There are around 50 radiopharmaceuticals with U.S. FDA approval available for both therapeutic and diagnostic uses, with Technetium alone having over 30 approved compounds.

Business Dynamics

In order to increase their market presence, industry players are focusing on a variety of inorganic growth tactics including partnership and cooperation agreements, which is anticipated to accelerate the growth of the worldwide radiopharmaceuticals in nuclear medicine market over the forecast period. For instance, a distribution contract was signed by Cardinal Health Inc. and Telix Pharmaceuticals Inc., a division of Telix Pharmaceuticals Limited, in October 2018. In accordance with the contract, Cardinal Health will provide the 69Ga-PSMA Kit as well as create unit dosages of 68Ga-PSMA delivered as an investigational product for use in clinical trials sponsored by qualified investigators, including those sponsored by Telix.

Important aspects of the study:

• Using 2019 as the base year, this research analyses the global market for radiopharmaceuticals used in nuclear medicine and offers market size (US$ Mn) and compound annual growth rate (CAGR%) for the projected period (2020–2027).

• It presents appealing investment proposition matrices for this industry and clarifies prospective revenue prospects across various categories.

• This research also offers important insights into market trends, opportunities, new product launches or approvals, market drivers, restraints, trends in regional markets, and competitive tactics used by prominent competitors.

Comments

Post a Comment

Popular posts from this blog

Infusion Pumps Market to Surpass US$ 5,709.1 Million with a CAGR of 6.1% by 2027

-
Image
A medical device called an infusion pump is used to administer different fluids to the body under controlled conditions. In hospitals, nursing homes, long-term care facilities, and residential settings, the pump is used to provide intravenous medications. Infusion pumps are used in the treatment and management of diabetes, gastroenterology, haematology, neonatology, analgesia, and chemotherapy. The global infusion pumps market is estimated to account for US$ 5,709.1 Mn in terms of value by 2027. Market drivers for infusion pumps worldwide: When treating diabetes, insulin is given by infusion pumps. Therefore, during the course of the forecast period, rising diabetes prevalence is anticipated to fuel market expansion for infusion pumps worldwide. The American Diabetes Association estimates that there were more than 500 million prevalent instances of type 2 diabetes worldwide in 2018. Important aspects of the study: ▪️ In-depth research of the global infusion pump market is provided in
Read more

Herceptin Biosimilars Market Impact of Existing and Emerging Flexible Trends, Promising Growth Opportunities | Forecasts 2022-2028- Coherent Market Insights

-
Image
The  Herceptin Biosimilar Market  is carefully analyzed in the report with an emphasis on market dynamics, including key issues and challenges, drivers, trends, and opportunities. The report includes an in-depth analysis of significant market players to understand the utilization of the main strategies that have been adopted in the Herceptin Biosimilar market. It also sheds light on the industrial value chain and its expected changes over the forecast period. Herceptin is a monoclonal antibody used to treat patients suffering from metastatic (spread) breast cancer and gastric cancers. Hereceptin is used as part of chemotherapy regimen for adjuvant treatment of lymph-node positive, HER2/neu protein positive breast cancer. Herceptin is also known as trastuzumab and mainly administered intravenously in cancer patients, the dose of herceptin given to patients is evaluated on the basis of patients' disease history and other physiological factors such as height, weight, type of cancer or
Read more